Search Page

1

Cite

Share

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. Gersh BJ, et al. Among authors: fifer ma. Circulation. 2011 Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230. Epub 2011 Nov 8. Circulation. 2011. PMID: 22068435 No abstract available.

Cite

Share

2

Cite

Share

Evaluating Histopathology to Improve Our Understanding of Hypertrophic Cardiomyopathy.

Rowin EJ, Fifer MA. Rowin EJ, et al. Among authors: fifer ma. J Am Coll Cardiol. 2021 May 4;77(17):2171-2173. doi: 10.1016/j.jacc.2021.03.292. J Am Coll Cardiol. 2021. PMID: 33926652 Free article. No abstract available.

Cite

Share

3

Cite

Share

Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy.

Fifer MA. Fifer MA. J Am Coll Cardiol. 2018 Dec 18;72(24):3095-3097. doi: 10.1016/j.jacc.2018.10.013. J Am Coll Cardiol. 2018. PMID: 30545447 Free article. No abstract available.

Cite

Share

4

Cite

Share

Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.

Shimada YJ, Raita Y, Liang LW, Maurer MS, Hasegawa K, Fifer MA, Reilly MP. Shimada YJ, et al. Among authors: fifer ma. Circ Heart Fail. 2021 Jul;14(7):e007849. doi: 10.1161/CIRCHEARTFAILURE.120.007849. Epub 2021 Jul 1. Circ Heart Fail. 2021. PMID: 34192899

Cite

Share

5

Cite

Share

Choice of Septal Reduction Therapies and Alcohol Septal Ablation.

Fifer MA. Fifer MA. Cardiol Clin. 2019 Feb;37(1):83-93. doi: 10.1016/j.ccl.2018.08.009. Epub 2018 Oct 29. Cardiol Clin. 2019. PMID: 30447719 Review.

Cite

Share

6

Cite

Share

Difference in Metabolomic Response to Exercise between Patients with and without Hypertrophic Cardiomyopathy.

Shimada YJ, Batra J, Kochav SM, Patel P, Jung J, Maurer MS, Hasegawa K, Reilly MP, Fifer MA. Shimada YJ, et al. Among authors: fifer ma. J Cardiovasc Transl Res. 2021 Apr;14(2):246-255. doi: 10.1007/s12265-020-10051-2. Epub 2020 Jun 27. J Cardiovasc Transl Res. 2021. PMID: 32594362

Cite

Share

7

Cite

Share

Management of symptoms in hypertrophic cardiomyopathy.

Fifer MA, Vlahakes GJ. Fifer MA, et al. Circulation. 2008 Jan 22;117(3):429-39. doi: 10.1161/CIRCULATIONAHA.107.694158. Circulation. 2008. PMID: 18212300 Review. No abstract available.

Cite

Share

8

Cite

Share

Percutaneous coronary interventions without on-site cardiac surgical backup.

Shahian DM, Meyer GS, Yeh RW, Fifer MA, Torchiana DF. Shahian DM, et al. Among authors: fifer ma. N Engl J Med. 2012 May 10;366(19):1814-23. doi: 10.1056/NEJMra1109616. N Engl J Med. 2012. PMID: 22571203 Review. No abstract available.

Cite

Share

9

Cite

Share

Exercise Oscillatory Ventilation in Hypertrophic Cardiomyopathy.

Sakellaropoulos SG, Baggish AL, Fifer MA, Lewis GD. Sakellaropoulos SG, et al. Among authors: fifer ma. Curr Probl Cardiol. 2022 May;47(5):100911. doi: 10.1016/j.cpcardiol.2021.100911. Epub 2021 May 29. Curr Probl Cardiol. 2022. PMID: 34210521 Review.

Cite

Share

10

Cite

Share

Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning.

Liang LW, Fifer MA, Hasegawa K, Maurer MS, Reilly MP, Shimada YJ. Liang LW, et al. Among authors: fifer ma. Circ Genom Precis Med. 2021 Jun;14(3):e003259. doi: 10.1161/CIRCGEN.120.003259. Epub 2021 Apr 23. Circ Genom Precis Med. 2021. PMID: 33890823 Clinical Trial.

Cite

Share